Scarica l'app Stockscreener
102.02
3.41%
-3.60
Dopo l'orario di chiusura:
97.51
-4.51
-4.42%
Precedente Chiudi:
$105.62
Aprire:
$109.43
Volume 24 ore:
688.68K
Relative Volume:
0.92
Capitalizzazione di mercato:
$2.59B
Reddito:
$302.00K
Utile/perdita netta:
$-117.10M
Rapporto P/E:
-9.1662
EPS:
-11.13
Flusso di cassa netto:
$-129.13M
1 W Prestazione:
-7.89%
1M Prestazione:
+57.66%
6M Prestazione:
+431.91%
1 anno Prestazione:
+849.91%
Intervallo 1D:
$100.07
$109.55
Intervallo di 1 settimana:
$100.07
$121.21
Portata 52W:
$10.37
$121.21
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Nome
Cidara Therapeutics Inc
Settore
Industria
Telefono
858-752-6170
Indirizzo
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Confronta CDTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
102.02 | 2.81B | 302.00K | -117.10M | -129.13M | -11.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Iniziato | Morgan Stanley | Overweight |
| 2025-10-10 | Iniziato | JP Morgan | Overweight |
| 2025-06-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-12 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-01-27 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-08 | Iniziato | Guggenheim | Buy |
| 2024-08-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | Ripresa | H.C. Wainwright | Buy |
| 2021-09-22 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | Iniziato | Aegis Capital | Buy |
| 2019-09-04 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-07-26 | Iniziato | Citigroup | Buy |
| 2017-04-21 | Iniziato | Raymond James | Strong Buy |
| 2017-04-17 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-04-11 | Ripresa | Wedbush | Outperform |
| 2017-02-22 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-22 | Aggiornamento | WBB Securities | Sell → Hold |
| 2016-12-21 | Ripresa | Leerink Partners | Outperform |
| 2016-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2016-09-23 | Downgrade | WBB Securities | Hold → Sell |
| 2015-10-09 | Aggiornamento | WBB Securities | Sell → Hold |
| 2015-05-11 | Iniziato | Jefferies | Buy |
| 2015-05-11 | Iniziato | Leerink Partners | Outperform |
| 2015-05-11 | Iniziato | Needham | Buy |
| 2015-05-11 | Iniziato | Wedbush | Outperform |
| 2015-04-23 | Iniziato | WBB Securities | Sell |
Mostra tutto
Cidara Therapeutics Inc Borsa (CDTX) Ultime notizie
Cidara Therapeutics Inc.’s volatility index tracking explainedStock Surge & Reliable Momentum Entry Alerts - newser.com
Morgan Stanley Backs Cidara Therapeutics (CDTX) with $190 Price Target - GuruFocus
Cidara Therapeutics gains overweight rating at Morgan Stanley - Seeking Alpha
Morgan Stanley Initiates Coverage on CDTX with Overweight Rating - GuruFocus
Morgan Stanley Initiates Cidara Therapeutics at Overweight With $190 Price Target - MarketScreener
Analyzing drawdowns of Cidara Therapeutics Inc. with statistical toolsQuarterly Market Summary & Verified Momentum Watchlists - newser.com
Will Cidara Therapeutics Inc. stock deliver long term returnsMarket Growth Report & Safe Capital Growth Trade Ideas - newser.com
How risky is Cidara Therapeutics Inc. stock nowPortfolio Gains Summary & Reliable Price Breakout Alerts - newser.com
How Cidara Therapeutics Inc. stock compares to growth peers2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Can Cidara Therapeutics Inc. (20D0) stock reach $200 price targetJuly 2025 Setups & Detailed Earnings Play Strategies - newser.com
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 - MarketScreener
How Cidara Therapeutics Inc. stock benefits from strong dollarPortfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
Can machine learning forecast Cidara Therapeutics Inc. recoveryWeekly Trade Report & Verified Stock Trade Ideas - newser.com
Cidara to present phase 2 data on influenza drug at ID Week 2025 - Investing.com
Cidara Therapeutics to Present Late-Breaking Phase 2 Data on CD388 for Influenza at ID Week 2025 - Quiver Quantitative
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 - The Manila Times
Can you recover from losses in Cidara Therapeutics Inc.Weekly Profit Summary & Stepwise Trade Execution Plans - newser.com
What hedge fund moves indicate for Cidara Therapeutics Inc. (20D0) stockJuly 2025 EndofMonth & Low Drawdown Momentum Ideas - newser.com
Using Ichimoku Cloud for Cidara Therapeutics Inc. technicals2025 AllTime Highs & Consistent Return Strategy Ideas - newser.com
What institutional flow reveals about Cidara Therapeutics Inc.Quarterly Trade Report & Verified Momentum Stock Alerts - newser.com
Cidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Now Covered by JPMorgan Chase & Co. - MarketBeat
JP Morgan Initiates Coverage on CDTX with Overweight Rating | CD - GuruFocus
Cidara Therapeutics (CDTX) Is Up 10.8% After FDA Grants Breakthrough Therapy Designation to CD388 - Sahm
WBB Securities Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - MarketBeat
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive' - Benzinga
Why Cidara Therapeutics (CDTX) Is Up 12.4% After Breakthrough Therapy Status for Novel Flu Drug CD388 - Yahoo Finance
Cidara Therapeutics (NASDAQ:CDTX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $150.00 - MarketBeat
Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage - Benzinga
Cidara Therapeutics stock price target raised to $150 at H.C. Wainwright - Investing.com Canada
JP Morgan Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation - Nasdaq
How to build a dashboard for Cidara Therapeutics Inc. stockWeekly Risk Summary & AI Enhanced Trading Signals - newser.com
JPMorgan Initiates Coverage on Cidara Therapeutics With Overweight Rating, $200 Price Target - MarketScreener
Forecasting Cidara Therapeutics Inc. price range with options data2025 Volatility Report & Stepwise Swing Trade Plans - newser.com
Biotech And Healthcare Stocks Hit 52-Week Highs: Is The Momentum Sustainable? - Nasdaq
Why Cidara Therapeutics Inc. stock could be next big winnerQuarterly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Cidara Therapeutics' (CDTX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Why Cidara Therapeutics Stock Crushed It Today - sharewise.com
WBB Securities Maintains Cidara Therapeutics (CDTX) Strong Buy Recommendation - Nasdaq
HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation - Nasdaq
CDTX Surges on FDA's Breakthrough Therapy Designation - GuruFocus
Cidara Therapeutics Inc Azioni (CDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cidara Therapeutics Inc Azioni (CDTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 26 '25 |
Buy |
44.00 |
2,272,727 |
99,999,988 |
3,365,523 |
| Mineo Chrysa | Director |
Jun 02 '25 |
Buy |
21.71 |
2,270 |
49,281 |
2,270 |
| Mineo Chrysa | Director |
Jun 03 '25 |
Buy |
23.44 |
1,050 |
24,614 |
3,320 |
| Ward Shane | COO & CLO |
Mar 11 '25 |
Sale |
21.96 |
1,664 |
36,542 |
14,674 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):